Sihuan Pharma Starts China Phase II Lung Cancer Trial

Sihuan Pharma has started a China Phase II Trial of pirotinib, a novel EGFR treatment for cancer, in patients with non-small cell lung cancer (NSCLC). The company conducted the earlier Phase I trial in the US. Sihuan, which claims to be the largest cardio-cerebral vascular drug maker in China, developed the candidate through its own R&D efforts. Sihuan was the first China biopharma to privatize from an ex-China exchange and then re-list in China, raising $741 million in a 2010 Hong Kong IPO. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:

Original Article: Sihuan Pharma Starts China Phase II Lung Cancer Trial

More From BioPortfolio on "Sihuan Pharma Starts China Phase II Lung Cancer Trial"